ABSTRACT
Up to one of every six individuals diagnosed with one cancer will be diagnosed with a second primary cancer in their lifetime. Genetic factors contributing to the development of multiple primary cancers, beyond known cancer syndromes, have been underexplored. To characterize genetic susceptibility to multiple cancers, we conducted a pan-cancer, whole-exome sequencing study of individuals drawn from two large prospective cohorts (6,429 cases, 165,853 controls). We created two groupings of individuals diagnosed with multiple primary cancers: 1) an overall combined set with at least two cancers across any of 36 organ sites; and 2) cancer-specific sets defined by an index cancer at one of 16 organ sites with at least 50 cases from each study population. We then investigated whether variants identified from exome sequencing were associated with these sets of multiple cancer cases in comparison to individuals with one and, separately, no cancers. We identified 22 variant-phenotype associations, 10 of which have not been previously discovered and were significantly overrepresented among individuals with multiple cancers, compared to those with a single cancer. Overall, we describe variants and genes that may play a fundamental role in the development of multiple primary cancers and improve our understanding of shared mechanisms underlying carcinogenesis. Further investigation of these findings may lead to new screening strategies for individuals at risk for multiple primary cancers.
Competing Interest Statement
J.S. Witte is a non-employee, cofounder of Avail Bio. E. Jorgenson and additional authors listed under "Regeneron Genetics Center" are full-time employees of Regeneron Pharmaceuticals. No disclosures were reported for the other authors.
Funding Statement
This material is based upon work supported by NIH grant R01 CA201358, RC2 AG036607, and the National Science Foundation Graduate Research Fellowship Program under Grant No. 1650113. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation. Support for study enrollment, survey administration, and biospecimen collection of Kaiser Permanente Research Bank participants was provided by the Robert Wood Johnson Foundation, the Wayne and Gladys Valley Foundation, the Ellison Medical Foundation, and Kaiser Permanente national and regional community benefit programs. Additionally, REG is supported by a Young Investigator Award from the Prostate Cancer Foundation. This research has been conducted using the UK Biobank Resource under Application Number 14015. Furthermore, the authors thank the Regeneron Genetics Center for covering the costs of whole-exome sequencing of the Kaiser Permanente Research Bank study participants.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research was conducted with approved access to UK Biobank data under application number 14105 (PI: Witte) and in accordance with the UK Biobank Ethics and Governance Framework. Uk Biobank data are publicly available by request from https://www.ukbiobank.ac.uk. The de-identified participants from the Kaiser Permanente Research Bank were obtained with approval under UCSF IRB number 16-19699 (PI: Witte). Access to and use of data from the Kaiser Permanente Research Bank (KPRB) was approved by the KPRB Access Review Committee. The study was conducted under a waiver of informed consent approved by the Kaiser Permanente Northern California Institutional Review Board. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
CONFLICTS OF INTERESTS J.S. Witte is a non-employee, cofounder of Avail Bio. E. Jorgenson and additional authors listed under “Regeneron Genetics Center” are full-time employees of Regeneron Pharmaceuticals. No disclosures were reported for the other authors.
Data Availability
All results from this study are available from the article or Supplementary Materials. The UK Biobank cohort data is publicly available from the UK Biobank access portal at https://www.ukbiobank.ac.uk. The Kaiser Permanente Research Bank data are available on dbGAP. All remaining relevant data are available in the article, supplementary information, or from the corresponding author upon reasonable request.